Table of Contents
ISRN Gastroenterology
Volume 2013, Article ID 304894, 7 pages
http://dx.doi.org/10.1155/2013/304894
Clinical Study

Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan

Received 4 March 2013; Accepted 21 March 2013

Academic Editors: L. David, C.-T. Shun, and E. A. Wiemer

Copyright © 2013 Tsutomu Mizoshita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Baumgart and W. J. Sandborn, “Inflammatory bowel disease: clinical aspects and established and evolving therapies,” The Lancet, vol. 369, no. 9573, pp. 1641–1657, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Yamamoto, H. Nakase, M. Matsuura, S. Masuda, K. I. Inui, and T. Chiba, “Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis,” Journal of Clinical Gastroenterology, vol. 45, no. 6, pp. 526–530, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. B. E. Sands, “Inflammatory bowel disease: past, present, and future,” Journal of Gastroenterology, vol. 42, no. 1, pp. 16–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. W. A. Faubion, E. V. Loftus, W. S. Harmsen, A. R. Zinsmeister, and W. J. Sandborn, “The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study,” Gastroenterology, vol. 121, no. 2, pp. 255–260, 2001. View at Google Scholar · View at Scopus
  5. S. L. Swartz and R. G. Dluhy, “Corticosteroids: clinical pharmacology and therapeutic use,” Drugs, vol. 16, no. 3, pp. 238–255, 1978. View at Google Scholar · View at Scopus
  6. H. Ogata, T. Matsui, M. Nakamura et al., “A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis,” Gut, vol. 55, no. 9, pp. 1255–1262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. D. C. Baumgart, J. P. Pintoffl, A. Sturm, B. Wiedenmann, and A. U. Dignass, “Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease—a long-term follow-up,” American Journal of Gastroenterology, vol. 101, no. 5, pp. 1048–1056, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Fellermann, Z. Tanko, K. R. Herrlinger et al., “Response of refractory colitis to intravenous or oral tacrolimus (FK506),” Inflammatory Bowel Diseases, vol. 8, no. 5, pp. 317–324, 2002. View at Google Scholar · View at Scopus
  9. S. C. Ng, N. Arebi, and M. A. Kamm, “Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 13, no. 2, pp. 129–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Yamamoto, H. Nakase, S. Mikami et al., “Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 5, pp. 589–597, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Högenauer, H. H. Wenzl, T. A. Hinterleitner, and W. Petritsch, “Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 4, pp. 415–423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. D. A. Ziring, S. S. Wu, W. S. Mow, M. G. Martín, M. Mehra, and M. E. Ament, “Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 45, no. 3, pp. 306–311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Ogata, J. Kato, F. Hirai et al., “Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis,” Inflammatory Bowel Diseases, vol. 18, no. 5, pp. 803–808, 2012. View at Google Scholar
  14. T. Mizushima, S. Tanida, T. Mizoshita et al., “A complicated case of tacrolimus-induced rapid remission after cesarean section in the early third trimester for refractory severe ulcerative colitis flaring in the initial period of gestation,” Case Reports in Gastroenterology, vol. 5, no. 1, pp. 144–151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Naganuma, T. Fujii, and M. Watanabe, “The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease,” Journal of Gastroenterology, vol. 46, no. 2, pp. 129–137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Mizoshita, T. Tsukamoto, H. Nakanishi et al., “Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis,” Journal of Cancer Research and Clinical Oncology, vol. 129, no. 12, pp. 727–734, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Tatematsu, T. Tsukamoto, and T. Mizoshita, “Role of Helicobacter pylori in gastric carcinogenesis: the origin of gastric cancers and heterotopic proliferative glands in mongolian gerbils,” Helicobacter, vol. 10, no. 2, pp. 97–106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Mizoshita, T. Tsukamoto, K. I. Inada et al., “Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon,” Histology and Histopathology, vol. 22, no. 1–3, pp. 251–260, 2007. View at Google Scholar · View at Scopus
  19. M. P. Buisine, P. Desreumaux, E. Leteurtre et al., “Mucin gene expression in intestinal epithelial cells in Crohn's disease,” Gut, vol. 49, no. 4, pp. 544–551, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Shaoul, Y. Okada, E. Cutz, and M. A. Marcon, “Colonic expression of MUC2, MUC5AC, and TFF1 in inflammatory bowel disease in children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 38, no. 5, pp. 488–493, 2004. View at Google Scholar · View at Scopus
  21. N. Tatsumi, R. Kushima, M. Vieth et al., “Cytokeratin 7/20 and mucin core protein expression in ulcerative colitis-associated colorectal neoplasms,” Virchows Archiv, vol. 448, no. 6, pp. 756–762, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Takeda, S. Ban, H. Iseki, Y. Otani, and I. Koyama, “Gastric differentiation markers expression is potentially useful for the detection of ulcerative colitis-associated dysplasias,” Hepato-Gastroenterology, vol. 56, no. 89, pp. 252–253, 2009. View at Google Scholar · View at Scopus
  23. K. W. Schroeder, W. J. Tremaine, and D. M. Ilstrup, “Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study,” The New England Journal of Medicine, vol. 317, no. 26, pp. 1625–1629, 1987. View at Google Scholar · View at Scopus
  24. L. R. Sutherland, F. Martin, and S. Greer, “5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis,” Gastroenterology, vol. 92, no. 6, pp. 1894–1898, 1987. View at Google Scholar · View at Scopus
  25. M. E. Forgue-Lafitte, B. Fabiani, P. P. Levy, N. Maurin, J. F. Flejou, and J. Bara, “Abnormal expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative colitis and cancer,” International Journal of Cancer, vol. 121, no. 7, pp. 1543–1549, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Borralho, A. Vieira, J. Freitas, P. Chaves, and J. Soares, “Aberrant gastric apomucin expression in ulcerative colitis and associated neoplasia,” Journal of Crohn's and Colitis, vol. 1, no. 1, pp. 35–40, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Watanabe, T. Konishi, J. Kishimoto, K. Kotake, T. Muto, and K. Sugihara, “Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study,” Inflammatory Bowel Diseases, vol. 17, no. 3, pp. 802–808, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Yao, S. Tsutsumi, Y. Akaiwa et al., “Phenotypic expression of colorectal adenocarcinomas with reference to tumor development and biological behavior,” Japanese Journal of Cancer Research, vol. 92, no. 7, pp. 755–761, 2001. View at Google Scholar · View at Scopus
  29. D. C. Baumgart, J. K. Macdonald, and B. Feagan, “Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD007216, 2008. View at Google Scholar · View at Scopus
  30. K. Fellermann, D. Ludwig, M. Stahl, T. David-Walek, and E. F. Stange, “Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506),” American Journal of Gastroenterology, vol. 93, no. 10, pp. 1860–1866, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Matsuhashi, A. Nakajima, K. Watanabe et al., “Tacrolimus in corticosteroid-resistant ulcerative colitis,” Journal of Gastroenterology, vol. 35, no. 8, pp. 635–640, 2000. View at Google Scholar · View at Scopus
  32. K. R. Herrlinger, D. N. Barthel, K. J. Schmidt et al., “Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 9, pp. 1036–1041, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Yamamoto, H. Nakase, M. Matsuura et al., “Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus,” Journal of Gastroenterology and Hepatology, vol. 25, no. 5, pp. 886–891, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Benson, T. Barrett, M. Sparberg, and A. L. Buchman, “Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience,” Inflammatory Bowel Diseases, vol. 14, no. 1, pp. 7–12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Ljung, O. Ø. Thomsen, M. Vatn et al., “Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia,” Scandinavian Journal of Gastroenterology, vol. 42, no. 2, pp. 221–227, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Suzuki, N. Yoshimura, A. R. Saniabadi, and Y. Saito, “Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study,” Digestive Diseases and Sciences, vol. 49, no. 4, pp. 565–571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Ozeki, S. Tanida, T. Mizushima et al., “Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis induced clinical remission in a Crohn's disease patient with the loss of response to scheduled adalimumab maintenance therapy: a case report,” Internal Medicine, vol. 51, no. 6, pp. 595–599, 2012. View at Google Scholar
  38. T. Mizoshita, S. Tanida, S. Kusumoto et al., “Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia,” Clinical Journal of Gastroenterology, vol. 5, no. 4, pp. 302–306, 2012. View at Google Scholar
  39. S. J. H. Van Deventer, “Tumour necrosis factor and Crohn's disease,” Gut, vol. 40, no. 4, pp. 443–448, 1997. View at Google Scholar · View at Scopus
  40. N. Kashiwagi, I. Hirata, and R. Kasukawa, “A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis,” Therapeutic Apheresis, vol. 2, no. 2, pp. 134–141, 1998. View at Google Scholar · View at Scopus
  41. A. R. Saniabadi, H. Hanai, K. Takeuchi et al., “Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes,” Therapeutic Apheresis, vol. 7, no. 1, pp. 48–59, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Sakuraba, S. Motoya, K. Watanabe et al., “An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment,” American Journal of Gastroenterology, vol. 104, no. 12, pp. 2990–2995, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Yamamoto, S. Umegae, and K. Matsumoto, “Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis,” Journal of Crohn's and Colitis, vol. 6, no. 7, pp. 750–755, 2012. View at Google Scholar